373 related articles for article (PubMed ID: 16841141)
1. FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Zimny M; Gagel B; DiMartino E; Hamacher K; Coenen HH; Westhofen M; Eble M; Buell U; Reinartz P
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1426-31. PubMed ID: 16841141
[TBL] [Abstract][Full Text] [Related]
2. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.
Gagel B; Reinartz P; Dimartino E; Zimny M; Pinkawa M; Maneschi P; Stanzel S; Hamacher K; Coenen HH; Westhofen M; Büll U; Eble MJ
Strahlenther Onkol; 2004 Oct; 180(10):616-22. PubMed ID: 15480509
[TBL] [Abstract][Full Text] [Related]
3. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?
Gagel B; Piroth M; Pinkawa M; Reinartz P; Zimny M; Kaiser HJ; Stanzel S; Asadpour B; Demirel C; Hamacher K; Coenen HH; Scholbach T; Maneschi P; DiMartino E; Eble MJ
BMC Cancer; 2007 Jun; 7():113. PubMed ID: 17598907
[TBL] [Abstract][Full Text] [Related]
4. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
5. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
[TBL] [Abstract][Full Text] [Related]
6. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
7. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode.
Mortensen LS; Buus S; Nordsmark M; Bentzen L; Munk OL; Keiding S; Overgaard J
Acta Oncol; 2010 Oct; 49(7):934-40. PubMed ID: 20831480
[TBL] [Abstract][Full Text] [Related]
8. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
10. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
Lawrentschuk N; Poon AM; Foo SS; Putra LG; Murone C; Davis ID; Bolton DM; Scott AM
BJU Int; 2005 Sep; 96(4):540-6. PubMed ID: 16104907
[TBL] [Abstract][Full Text] [Related]
11. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
12. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
[TBL] [Abstract][Full Text] [Related]
13. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
[TBL] [Abstract][Full Text] [Related]
14. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
Wyss MT; Honer M; Schubiger PA; Ametamey SM
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):311-8. PubMed ID: 16258762
[TBL] [Abstract][Full Text] [Related]
15. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
16. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
17. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
Rajendran JG; Schwartz DL; O'Sullivan J; Peterson LM; Ng P; Scharnhorst J; Grierson JR; Krohn KA
Clin Cancer Res; 2006 Sep; 12(18):5435-41. PubMed ID: 17000677
[TBL] [Abstract][Full Text] [Related]
18. Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose-18F-fluorothymidine- 18F-fluoromisonidazole-PET/CT study and human papillomavirus status in patients with head and neck cancer.
Cegla P; Joanna K; Sebastian G; Julian M; Michal S; Witold C
Nucl Med Commun; 2019 Jul; 40(7):752-757. PubMed ID: 30925543
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]